Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinic... (neinc.com . Safe Harbor State...)

Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program

Date:9/8/2009

neinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the standard carboplatin and paclitaxel response rate will not be improved as a result of the combination therapy and the risk that the results of the subsequent stage for this trial will not be consistent with the results of the first stage. Factors that could cause actual results to differ materially or otherwise adversely impact the company's ability to obtain regulatory approval for its product candidates include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2009 and the quarterly report on Form 10-Q for the quarter ended July 31, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Phar
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:12/16/2009)... has passed as fact among historians, journalists and politicians, ... the floor of the U.S. Congress: British forces used ... , But that claim has never been fully ... a historian at Colgate University. According to Douglas,s research, ... of Modern History , no such incident ever occurred. ...

(Date:12/16/2009)... cause of death from roadside bombs to freeway crashes. ... age 4 to 44, often overwhelms the body,s natural ... natural process, a team led by Erin Lavik, a ... her former doctoral student, James P. Bertram, built synthetic ... bleeding., Their work is published in Science Translational ...

(Date:12/16/2009)... Nursing Care at Hahnemann among the Best in ... -- Hahnemann University Hospital proudly announces it has ... Credentialing Center,s (ANCC) Magnet Recognition Program(R). Magnet(R) is ... hospital or medical center can achieve, and places ... the country that have achieved this prestigious distinction. ...

(Date:12/16/2009)... Resources, one of the world,s leading research and ... that, according to responses from surveyed dermatologists, Centocor ... inhibitors) will capture 22 percent of the biologics ... moderate to severe psoriasis. Among these two agents, ... times as much patient share as briakinumab. ...

Breaking Biology Technology:Despite claims, UK did not gas Iraqis in the 1920s, new research finds 2 Despite claims, UK did not gas Iraqis in the 1920s, new research finds 3 Despite claims, UK did not gas Iraqis in the 1920s, new research finds 4 Researchers take the inside route to halt bleeding 2 Hahnemann University Hospital Granted Magnet(R) Status 2 Hahnemann University Hospital Granted Magnet(R) Status 3 In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 2 In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 3

[0] Despite claims, UK did not gas Iraqis in the 1920s, new research finds [0] Researchers take the inside route to halt bleeding [0] Hahnemann University Hospital Granted Magnet(R) Status [0] In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market

... , , , ... CypHer ™ 5, a ... screening (1). CypHer5 has been used to obtain dose-response and ... β2-adrenergic receptor expressing cells (2). For live-cell receptor internalization studies, ...

... , Key words: ... Analyzer ● gene delivery, ... and primary cells can greatly aid secondary screening as well as ... stable cell systems to express target genes of interest at detectable ...

... Key words: adenoviral vector ... delivery, , ... can greatly aid secondary screening as well as lead and target ... to express target genes of interest at detectable levels is time-consuming. ...

Screening for potential beta 2-adrenergic receptor antagonists using CypHer5E and IN Cell Analyzer 1000 Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system

(Date:12/15/2009)... 15 The 2009 Frost & ... is presented to Sagem Securite (Safran Group) ... The award recognises the company,s expertise in ... in offering novel, value-added products to end ... ) ,, "Sagem Securite has been involved ...

(Date:12/15/2009)... San Diego, California, has been awarded an accreditation ... on results of a recent onsite inspection. ... this national recognition and congratulated for the "excellence ... GenWay Clinical Laboratory is one of nearly 7,000 ... Program, begun in the early 1960s, is recognized ...

(Date:12/15/2009)... available in German . , Leipzig: Species ... the future distribution of mammals. This is the finding ... indigenous European mammals. The researchers analysed data on species ... the phylogenetic information of the species. Judging by the ... species, mammals seem to adapt fast to changing climatic ...

Breaking Biology News(10 mins):Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 2 Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 3 Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 4 Species distribution models are of only limited value for predicting future mammal distributions 2 If Mom or Dad Is Depressed Kids Need Help Too 48500 1 If Mom or Dad Is Depressed Kids Need Help Too 48500 2 If Mom or Dad Is Depressed Kids Need Help Too 48500 3 Highmark to Sponsor Partners for a Healthy Community Event in Uniontown 48495 1 Highmark to Sponsor Partners for a Healthy Community Event in Uniontown 48495 2 Highmark to Sponsor Partners for a Healthy Community Event in Uniontown 48495 3 PharmaNet Development Group Clinical Research Experts to Present at Global Professional Meetings in June 12569 1 PharmaNet Development Group Clinical Research Experts to Present at Global Professional Meetings in June 12569 2

[0] Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems [0] GenWay Clinical Laboratory receives accreditation from College of American Pathologists [0] Species distribution models are of only limited value for predicting future mammal distributions

... Scientists at the Helmholtz-Zentrum fr Infektionsforschung (HZI) in ... better understanding metabolic pathways in bacteria and their ... Biology" working group, headed up by Vtor Martins ... necessary for increasing the production of biosynthetics in ...

... ANN ARBOR, Mich.---A "living fossil" tree species is helping ... responded to past climate change and how they may ... The research appears in the November issue of the ... widespread tropical tree with a history that goes back ...

... from foes, biologically speaking. Naturally produced in the ... break up blood clots and recruit clean-up cells ... fact, urokinase manufactured as a drug effectively clears ... plasminogen. , However, despite the efficacy of ...

Other Biology News:Biosynthetics production with detours 2 'Living fossil' tree contains genetic imprints of rain forests under climate change 2 Friend or foe? How the body's clot-busting system speeds up atherosclerosis 2 Friend or foe? How the body's clot-busting system speeds up atherosclerosis 3

Biosynthetics production with detours 'Living fossil' tree contains genetic imprints of rain forests under climate change Friend or foe? How the body's clot-busting system speeds up atherosclerosis

... vesicles are used to study co-translational ... Processing events such as signal peptide ... glycosylation can be examined by the ... vitro in the presence of these ...

Procollagen type I C-terminal propeptide (human, PICP)...

... Small Molecule Localization in Early Drug Development ... Get essential drug compound localization data ... Protein Discoverys imaging mass spectrometry service maps ... with histological images so you can localize ...

... LC Sciences provides a unique new tool, ... synthesis serving diverse needs in genomics, proteomics, ... OligoMix is a MIXTURE of a large ... delivered in a single microtube. OligoMix is ...

Biology Products:

Canine Pancreatic Microsomal Membranes from Promega Mouse Anti-Human Procollagen type I C-terminal propeptide (PICP) Monoclonal Antibody, Unconjugated from AntibodyShop A/S Imaging Mass Spectrometry for Small Molecule Localization from Protein Discovery, Inc.DNA OligoMix from LC Sciences

Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinic...(neinc.com . Safe Harbor State...)